Actuate Therapeutics got approval for a patent on its elraglusib oral tablets, helping its cancer treatment progress.

Nov 2, 2026, 9:34 AM ETTrialRead the original at globenewswire.com

Good for ACTU

The U.S. allowance for an elraglusib tablet patent could strengthen protection, and a daily tablet may make dosing easier. The planned Phase 1/2 study is not due to start until Q1 2027, so these benefits remain untested.

ACTU · Actuate Therapeutics, Inc.

AI read · Good for ACTU

The AI's read

Patent protection may give Actuate more control over its tablet form. Daily dosing and steadier drug levels could make the treatment easier to use. The planned Phase 1/2 study is not due to start until Q1 2027. The tablet’s benefits have not yet been tested in that study, but the allowance and proposed dosing improvements support the drug’s development.

Get alerts for ACTU

Follow Actuate Therapeutics, Inc. (ACTU) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for ACTU

Free on the App Store and Google Play, or on the web.